Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

by Schultze-Seemann, Wolfgang , Jilg, Cordula Annette , Drendel, Vanessa , Werner, Martin , Haverkamp, Christian , Krönig, Malte , Schulte, Antonia , Heinicke, Laura , Schaal, Kathrin , Wetterauer, Ulrich

in Adrenergic beta-agonists / Adrenergic beta-Antagonists - adverse effects / Aged / Combined Modality Therapy / Complications and side effects / Development and progression / Diabetes Mellitus - physiopathology / Diabetics / Follow-Up Studies / Humans / Lymphatic Metastasis / Male / Medicine / Medicine & Public Health / Middle Aged / Neoplasm Grading / Neoplasm Staging / Prognosis / Prostate cancer / Prostatectomy - adverse effects / Prostatic Neoplasms - etiology / Prostatic Neoplasms - secondary / Prostatic Neoplasms - surgery / Risk factors / Surgical Oncology

2017

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

2017

Confirm

Do you wish to request the book?

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

2017

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

Schultze-Seemann, Wolfgang,

Jilg, Cordula Annette,

Drendel, Vanessa,

Werner, Martin,

Haverkamp, Christian,

Krönig, Malte,

Schulte, Antonia,

Heinicke, Laura,

Schaal, Kathrin,

Wetterauer, Ulrich

2017

Overview

Background We evaluated the influence of comorbidity inferred risks for lymph node metastasis (pN1) and positive surgical margins (R1) after radical prostatectomy in order to optimize pretherapeutic risk classification. We analyzed 454 patients after radical prostatectomy (RP) between 2009 and 2014. Comorbidities were defined by patients’ medication from our electronic patient chart and stratified according to the ATC WHO code. Endpoints were lymph node metastasis (pN1) and positive surgical margins (R1). Results Rates for pN1 and R1 were 21.4% (97/454) and 29.3% (133/454), respectively. In addition to CAPRA and Gleason score, we identified diabetes as a significant medication inferred risk factor for pN1 (OR 2.9, p = 0.004/OR 3.2, p = 0.001/OR 3.5, p = 0.001) and beta-blockers for R1 (OR 1.9, p = 0.020/OR 2.9, p = 0.004). Patients with diabetes showed no statistically significant difference in Gleason score, CAPRA Score, PSA, and age compared to non-diabetic patients. Conclusions We identified diabetes and beta1 adrenergic blockage as significant risk factors for lymph node metastasis and positive surgical margins in prostate cancer (PCa). Patients at risk will need intensive pretherapeutic staging for optimal therapeutic stratification.

Share this book

Add to My Shelf

Publisher

BioMed Central,BioMed Central Ltd

Subject

Adrenergic beta-agonists

/ Adrenergic beta-Antagonists - adverse effects

/ Aged

/ Combined Modality Therapy

/ Complications and side effects

/ Development and progression

/ Diabetes Mellitus - physiopathology